Clinical Trials Logo

Cardiotoxicity clinical trials

View clinical trials related to Cardiotoxicity.

Filter by:

NCT ID: NCT06331806 Recruiting - Clinical trials for Cardiomyopathy Due to Drug

Myocardial Fibrosis Identification in Patients With Anthracycline-induced Cardiotoxicity

Start date: February 22, 2018
Phase: N/A
Study type: Interventional

This is an interventional study for patients who had developed Anthracycline-Induced Cardiotoxicity (AIC) during or after anthracycline-containing therapy, referred to the Cardioncology Unit for heart failure treatment

NCT ID: NCT06310330 Recruiting - Clinical trials for Breast Neoplasm Malignant Primary

TRUST-ACE - Anticancer-treatment Cardiotoxicity Identification by Echocardiography

TRUST-ACE
Start date: March 8, 2024
Phase: N/A
Study type: Interventional

TRUST-ACE will compare a simplified echocardiographic protocol focusing on ventricular function with the guideline recommended comprehensive echocardiographic examination using a randomised design in follow-up of breast-cancer patients with respect to identification of cancer treatment related cardiac dysfunction (CTRCD). Secondly, the study will evaluate whether novel tools used to improve standardization of recordings as well as automated measurements of central measurements, e.g. ejection fraction (EF) and global longitudinal strain (GLS) can improve the precision of echocardiography in daily clinical practice.

NCT ID: NCT06282796 Recruiting - Breast Cancer Clinical Trials

Early Prediction and Warning for Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy

Start date: January 1, 2024
Phase:
Study type: Observational

This multicenter clinical study aims to build an intelligent and accurate diagnosis and dynamic prediction and early warning model of cardiotoxicity due to anthracycline-based breast cancer chemotherapy, clarify the value of the early warning model in guiding the targeted prevention of myocardial protection, providing an important theoretical basis for reducing the mortality rate of breast cancer and improving the prognosis.

NCT ID: NCT06277388 Recruiting - Clinical trials for Non-small Cell Lung Cancer

Evaluation of Impedance Cardiography for Assessing Hemodynamic Shifts in Patients With LA-NSCLC During Treatment.

Start date: June 5, 2021
Phase:
Study type: Observational

This study aimed to investigate the role of impedance cardiography (ICG) in evaluating hemodynamic changes during the 6-minute walk test (6MWT) in patients with locally advanced non-small cell lung cancer (LA-NSCLC) who underwent combined concurrent chemoradiotherapy (CCRT) and immunotherapy. Additionally, It sought to analyze the predictive significance of cardiac parameters to both treatment toxicity and survival prognosis.

NCT ID: NCT06270667 Recruiting - Clinical trials for Cardiovascular Diseases

Effects of Exercise Training in Survivors of Lymphoma

LYMfit
Start date: March 20, 2024
Phase: N/A
Study type: Interventional

This study aims to compare the effects of aerobic exercise with or without addition of resistance exercise to usual care in individuals treated with anthracyclines for lymphomas and to compare exercise effects to age- and sex-matched individuals with no prior history of malignant diseases.

NCT ID: NCT06214195 Recruiting - Clinical trials for Cardiotoxicity Induced by Drug Therapy for Breast Cancer

The Use of Shengmai San to Prevent Anthracycline Sequential Trastuzumab Therapy Related Cardiac Toxicity

START
Start date: January 20, 2024
Phase: Phase 3
Study type: Interventional

To evaluate the effectiveness and safety of Shengmai San in preventing anthracycline sequential trastuzumab therapy related cardiac toxicity through a prospective randomized controlled study.

NCT ID: NCT06211413 Enrolling by invitation - Hypertension Clinical Trials

Hypertension and Arrhythmias in CLL Patients Treated With BTK Inhibitors

SENTINEL
Start date: February 7, 2024
Phase:
Study type: Observational

Acalabrutinib and Zanabrutinib are highly effective drugs used to treat Chronic Lymphocytic Leukemia, but they are associated with high blood pressure and abnormal heart rhythms. SENTINEL is an observational study that will use wearable technology to monitor heart rhythm and blood pressures at home to better understand how frequently patients are experiencing high blood pressure and/or abnormal heart rhythms.

NCT ID: NCT06183437 Recruiting - Cancer Clinical Trials

The STOP-MED CTRCD Trial

STOP-MED
Start date: March 4, 2024
Phase: Phase 4
Study type: Interventional

Cancer therapy-related cardiac dysfunction (CTRCD) is when the heart's ability to pump oxygenated blood to the body is compromised. It is a side effect of cancer therapy which can occur as commonly as in 1 in 5 patients. When this occurs, heart failure medications are started to protect the heart from progressing to heart failure. With early detection and treatment, heart function recovers to normal in >80% of patients. Unfortunately, heart failure medications are associated with an undesirable long-term pill burden, financial costs, and side-effects (e.g., dizziness and fatigue). As a result, cancer survivors frequently ask if they can safely stop their heart failure medications once their heart function has returned to normal. Currently there is no scientific evidence in this area of Cardio-Oncology. To address this knowledge gap, the investigators have designed a randomized control trial to assess the safety of stopping heart failure medication in patients with CTRCD and recovered heart function. The investigators will enrol patients who have completed their cancer therapy and are on heart medications for their CTRCD, which has now normalized. The investigators will randomize patients with no other reasons to continue heart failure medications (e.g., kidney disease) to continuing or stopping their heart medications safely. All patients will undergo a cardiac MRI at baseline, 1 and 5 years with safety assessments at 6-8 weeks, 6 and 9 months and 3 and 5 years. The investigators will determine if stopping medications is non-inferior to continuing medications by counting the numbers of patients who develop heart dysfunction by 1 year in each group.

NCT ID: NCT06155331 Recruiting - Clinical trials for Breast Cancer Stage 2 and 3

Evaluation of Possible Safety and Efficacy of Fenofibrate in the Prophylaxis of Doxorubicin Induced Cardiotoxicity in Breast Cancer Patients

Start date: December 2023
Phase: Phase 4
Study type: Interventional

This study aims at evaluating the possible safety and efficacy of fenofibrate in attenuating doxorubicin related cardiac toxicity in breast cancer patients.

NCT ID: NCT06132984 Recruiting - Clinical trials for Immune Checkpoint Inhibitors, Cardiotoxicity

Cardiac Magnetic Resonance Monitoring of Immune Checkpoint Inhibitor-related Cardiotoxicity

Start date: November 23, 2023
Phase:
Study type: Observational

This study is a prospective cohort clinical research that analyzes the changes in CMR parameters before and after immune checkpoint inhibitors (ICIs) therapy in patients with gynecologic malignancies. It also evaluates the value of CMR parameters in predicting long-term outcomes. The baseline assessment will be conducted prior to ICIs treatment, followed by multiple assessments during the medication process including within one week prior to cycle 3 , within the week prior to cycle 5 , 1 year after the first dose, and 2 years after the first dose. Assessment will also be conducted after discontinuation of ICIs medication. The assessment includes clinical assessment, CMR imaging, echocardiography, serum cardiac injury biomarkers, etc. Cancer therapy-related cardiac dysfunction (CTRCD), survival, and major adverse cardiac events (MACE) will be followed up.